Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004004771 - IMMUNOPOTENTIATING COMPOSITIONS

Publication Number WO/2004/004771
Publication Date 15.01.2004
International Application No. PCT/JP2003/008420
International Filing Date 02.07.2003
Chapter 2 Demand Filed 06.01.2004
IPC
A61K 31/7088 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
C12Q 1/02 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61K 38/1774
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
A61K 38/212
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons ; [IFN]
212IFN-alpha
A61K 39/3955
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
3955against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Applicants
  • ONO PHARMACEUTICAL CO., LTD. [JP]/[JP] (AllExceptUS)
  • HONJO, Tasuku [JP]/[JP]
  • MINATO, Nagahiro [JP]/[JP] (UsOnly)
  • IWAI, Yoshiko [JP]/[JP] (UsOnly)
  • SHIBAYAMA, Shiro [JP]/[JP] (UsOnly)
Inventors
  • HONJO, Tasuku
  • MINATO, Nagahiro
  • IWAI, Yoshiko
  • SHIBAYAMA, Shiro
Agents
  • OHIE, Kunihisa
Priority Data
2002-19449103.07.2002JP
2003-2984606.02.2003JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) IMMUNOPOTENTIATING COMPOSITIONS
(FR) COMPOSITIONS IMMUNOSTIMULANTES
(JA) 免疫賦活組成物
Abstract
(EN) Compositions for treating cancer or infectious diseases mediated by immunopotentiation which is caused by inhibiting a immunosuppressive signal induced by PD-1, PD-L1 or PD-L2; a therapeutic method using the same; methods of screening an immunopotentiator, an anticancer substance or a substance against infectious diseases contained in these compositions as the active ingredient; a cell line to be used in these screening methods; a method of evaluating an anticancer agent; and a mammal having cancer cells transplanted therein which is to be used in the evaluation. The above compositions inhibiting the function of PD-1, PD-L1 or PD-L2 are useful in treating cancer or infectious diseases.
(FR) L'invention concerne des compositions permettant de traiter le cancer ou les maladies infectieuses, grâce à une immunostimulation causée par l'inhibition d'un signal immunosuppresseur induit par PD-1, PD-L1 ou PD-L2, une méthode thérapeutique comprenant l'utilisation de ces compositions, des procédés de criblage permettant d'identifier un immunostimulant, une substance anticancéreuse ou une substance active contre les maladies infectieuses présente dans ces compositions en tant que principe actif, une lignée cellulaire pouvant être utilisée dans ces procédés de criblage, un procédé d'évaluation d'un agent anticancéreux, et un mammifère dans lequel on a transplanté des cellules cancéreuses, et qui peut être utilisé pour une telle évaluation. Les compostions décrites inhibant la fonction de PD-1, PD-L1 ou PD-L2, peuvent être utilisées pour le traitement des cancers ou des maladies infectieuses.
(JA) PD-1、PD-L1またはPD-L2によって誘導される免疫抑制シグナルを阻害した結果惹起される免疫賦活を介した癌の治療若しくは感染症の治療のための組成物およびそれらを用いた治療方法、その有効成分として含まれる免疫賦活物質、癌治療物質若しくは感染症治療物質のスクリーニング方法、それらスクリーニング方法に使用される細胞株、癌治療物質を選別する評価法、およびその評価に用いられる癌細胞移植哺乳動物に関する。PD-1、PD-L1、またはPD-L2の機能を阻害する本発明の組成物は、癌または感染症に対する治療に有用である。
Latest bibliographic data on file with the International Bureau